Overview
PetIQ, Inc., a leading pet health and wellness company and portfolio company of Bansk Group, has completed the acquisition of MYOS Corp and its Fortetropin®-based muscle health product portfolio. The deal, announced on July 29, 2026, adds a clinically validated preventive-health pillar to PetIQ’s growing platform of OTC pet medications, supplements, and wellness brands.
Key Facts
At the core of every MYOS product is Fortetropin®, a proprietary, patented bioactive compound that supports muscle growth and preservation by modulating myostatin, the body’s natural regulator of muscle mass. The ingredient is backed by over a dozen clinical studies in dogs, cats, and horses, as well as a robust patent portfolio. Research has demonstrated that Fortetropin® helps build muscle, improve mobility, and reduce the rate of muscle loss associated with aging, injury, or surgery.
For PetIQ, which already dominates the OTC flea and tick, dental, and wellness categories through brands including PetArmor, Capstar, Minties, and VetIQ, the MYOS acquisition delivers entry into the fast-growing muscle health category — a preventive segment with strong veterinary endorsement. The product lines span both consumer-facing supplements and veterinary-exclusive formulations, deepening PetIQ’s relationship with the veterinary channel while leveraging its national retail and e-commerce footprint for scale.
Market Implications
The deal reflects a broader strategic shift in pet health: the convergence of OTC retail wellness and veterinary-grade preventive nutrition. Bansk Group, PetIQ’s private-equity owner with over $5 billion in assets under management, is clearly building a platform that spans treatment, prevention, and longevity. For competitors, the message is that science-backed ingredients with clinical dossiers are becoming table stakes in the premium wellness segment.
